Showing 22,212 results

Filters Content type: Editors' picks
Government, leadership & policy

UK: Labour manifesto drops key disability rights pledges

Editor's pick
Disability News Service
24 June 2024
Confidentiality, consent & medical ethics

What does the London NHS hospitals data theft mean for patients?

Editor's pick
The Guardian
24 June 2024
Injectable & long-acting PrEP

Unitaid calls for accelerated global access to long-acting HIV prevention drug lenacapavir after positive trial results

Editor's pick
Unitaid
21 June 2024
Injectable & long-acting PrEP

ICWEA Statement on Gilead’s announcement of twice-yearly Lenacapavir (LEN) for HIV prevention.

Editor's pick
International Community of Women living with HIV Eastern Africa
21 June 2024
Human rights

UNAIDS applauds Namibian Constitutional Court's decision to declare unconstitutional the law that had criminalised same-sex relationships

Editor's pick
UNAIDS
21 June 2024
Injectable & long-acting PrEP

Access Planning in High-Incidence, Resource-Limited Countries for Lenacapavir for HIV Prevention

Editor's pick
Gilead Sciences press release
21 June 2024
Pharmaceutical industry

Watch out, GSK. Gilead’s twice-yearly PrEP drug shows 100% efficacy for HIV prevention

Editor's pick
FiercePharma
21 June 2024
Neurological & cognitive problems

What Criteria Should Describe HIV-Related Cognitive Impairment?

Editor's pick
TheBodyPro
21 June 2024
Injectable & long-acting PrEP

Treatment Action Group Statement on Lenacapavir PrEP: Getting from Efficacy to Access Requires Generic Licensing and Cost Reductions

Editor's pick
Treatment Action Group
21 June 2024
Injectable & long-acting PrEP

“Long overdue long-acting products” A call to action to accelerate access to lenacapavir!

Editor's pick
AfroCAB
21 June 2024
Injectable & long-acting PrEP

Landmark Trial in South Africa and Uganda Finds Twice Yearly HIV Prevention Injection Safe and Highly Effective

Editor's pick
AVAC
20 June 2024
Injectable & long-acting PrEP

Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention

Editor's pick
Gilead Sciences press release
20 June 2024
Mpox (monkeypox)

South Africa Waits for Mpox Vaccines After Confirming Seven ‘Severe Cases’

Editor's pick
Health Policy Watch
20 June 2024
Bad science & bogus treatments

Old report about overseas Filipino workers with HIV falsely linked to Dubai

Editor's pick
AFP Factcheck
20 June 2024
HIV prevention policy

HIV prevention drug uptake is slow. Can offering choices change that?

Editor's pick
Devex (requires free registration)
20 June 2024
HIV testing programmes & uptake

In South Africa, traditional healers join the fight against HIV

Editor's pick
Associated Press
19 June 2024
Transgender people

Are trans men being forgotten in conversations about HIV prevention?

Editor's pick
Faculty of Public Health
19 June 2024
Young people

Caring, non-judgemental staff are the “magic ingredient” of youth-friendly HIV services

Editor's pick
Be In The Know
19 June 2024
Cardiovascular disease

Why a major finding on HIV and statins may not be that relevant in South Africa

Editor's pick
Spotlight
18 June 2024
Men who have sex with men (MSM)

Local Laws, Policies, and State-Level Politics Are Associated With PrEP Use Among Younger LGBTQ+ People

Editor's pick
TheBodyPro
18 June 2024
Pregnancy and vertical transmission

Why Does It Take So Long to Gather Antiretroviral Drug Safety Data for Pregnant People With HIV in the U.S.?

Editor's pick
TheBodyPro
18 June 2024
People who inject drugs

Community-based early HIV testing and treatment could successfully manage and prevent emerging HIV outbreaks among people who inject drugs, study suggests

Editor's pick
University of Bristol
17 June 2024
Activism & civil society

Meet Kenya’s inspiring HIV peer educators

Editor's pick
Be In The Know
17 June 2024
Government, leadership & policy

Welcome progress, but time to start doing things differently - what next for the HIV response in the UK

Editor's pick
National AIDS Trust
17 June 2024